Antibody medicines have now become a standardized pharmaceutical modality. With the spread of the production platforms in recent years, their pharmaceutical price per therapeutic cycle has become comparable to other molecular-targeted
drugs. Because of their high safety properties and long half-lives, they can be used in cases where small molecule drugs are ineffective or when there is an unmet need.
We pride ourselves on producing antibodies using our special method. Our antibody production technologies and research capabilities are our main strengths and have allowed us to not only obtain membrane proteins but also various types of antibodies against highly elusive targets. We are conducting research to develop revolutionary antibody medicines that we have never seen before.
However, with target depletion, a difficult issue in the discovery and development of antibody medicines, looming over us, efforts to develop antibody medicines cannot be sustained without the cooperation of academia. We strongly believe that sharing our skills, experiences, expertise, and human resources is key to the concerted and stimulating research and development of antibody medicines.